AbbVie Acquires Apogee Therapeutics for $10.9 Billion in Cash
AbbVie Inc. agreed to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, according to an announcement made Monday.
AbbVie Inc. (NYSE:) agreed to acquire Apogee Therapeutics (NASDAQ:) in an all-cash transaction valued at approximately $10.9 billion, the company announced Monday. The deal brings Apogee's clinical-stage immunology and respiratory pipeline under AbbVie's portfolio.
The $10.9 billion price represents a significant deployment of capital for AbbVie as the pharmaceutical giant continues reshaping its product portfolio. The transaction is structured entirely in cash, requiring no share issuance by AbbVie. No executives, counterparties, or advisors were named in the announcement.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.